Barclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)
In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exscientia Plc (EXAI – Research Report), with a price ...
Celebrate a Magical Holiday at The Marker Hotel
Step into a world of holiday enchantment at The Marker Hotel ( in San Francisco just off Union Square, where the spirit of ...
The Durango Herald5 天
The mind in motion: FLC mounts vibrant ‘Behind Me is Silence’
In the mysterious opening of “Behind Me is Silence,” 17 performers, one by one, silently walk through a dark landscape of ...
PRLD股票触及52周新低1.1美元，面临市场挑战
Prelude Therapeutics Inc (PRLD)股票已触及新的52周低点，交易价格为1.1美元，该公司正面临充满挑战的市场环境。这一最新价格标志着这家生物制药公司的重大下跌，过去一年其股票价值下降了65%。投资者正密切关注PRLD的表现，因为该公司正在经历一段波动期，并寻求在竞争激烈的生物科技板块重新站稳脚跟。52周低点成为该公司短期前景和潜在战略调整的关键指标。
Springworks Therapeutics: Strong Cash Position and Promising Drug Approval Outlook Justify ...
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Springworks Therapeutics (SWTX – Research ...